Perrigo Company plc Excess Tax Benefit from Share-based Compensation, Financing Activities
Perrigo Company plc (PRGO) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $2.50 million for the 9-month period ending 2015-03-28, per its 10-Q filed 2015-04-29.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2015-04-29
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-03-28 was -$1.30M.
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-12-27 was -$500.00K.
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-09-27 was $4.30M, a 40.28% decline year-over-year.
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-06-28 was -$700.00K, a 333.33% decline year-over-year.
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $5.70M, a 63.69% decline from fiscal 2013.
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $15.70M, a 21.71% increase from fiscal 2012.
- Perrigo Company plc excess tax benefit from share-based compensation, financing activities for fiscal 2012 was $12.90M.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2015-03-28 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | -$1.80M derived: sum of 2 quarters · filed 2015-04-29 | $2.50M 10-Q · filed 2015-04-29 | $1.80M derived: sum of 4 quarters · filed 2015-04-29 |
| 2014-12-27 | -$500.00K derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | $3.80M 10-Q · filed 2015-02-05 | $3.10M derived: sum of 3 quarters · filed 2015-02-05 | $2.60M derived: sum of 4 quarters · filed 2015-04-29 |
| 2014-09-27 | $4.30M 8-K · filed 2014-11-20 | $3.60M derived: sum of 2 quarters · filed 2014-11-20 | $3.10M derived: sum of 3 quarters · filed 2015-04-29 | $2.80M derived: sum of 4 quarters · filed 2015-04-29 |
| 2014-06-28 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-14 | -$1.20M derived: sum of 2 quarters · filed 2015-04-29 | -$1.50M derived: sum of 3 quarters · filed 2015-04-29 | $5.70M 10-K · filed 2014-08-14 |
| 2014-03-29 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | -$800.00K derived: sum of 2 quarters · filed 2015-04-29 | $6.40M 10-Q · filed 2015-04-29 | $6.70M derived: sum of 4 quarters · filed 2015-04-29 |
| 2013-12-28 | -$300.00K derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | $6.90M 10-Q · filed 2015-02-05 | $7.20M derived: sum of 3 quarters · filed 2015-02-05 | $6.90M derived: sum of 4 quarters · filed 2015-02-05 |
| 2013-09-28 | $7.20M 8-K · filed 2014-11-20 | $7.50M derived: sum of 2 quarters · filed 2014-11-20 | $7.20M derived: sum of 3 quarters · filed 2014-11-20 | |
| 2013-06-29 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-14 | $0.00 derived: sum of 2 quarters · filed 2014-08-14 | $15.70M 10-K · filed 2014-08-14 | |
| 2013-03-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $15.40M 10-Q · filed 2014-05-07 | ||
| 2012-12-29 | $15.70M 10-Q · filed 2014-02-06 | |||
| 2012-06-30 | $12.90M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |